-
April 25, 2013
GlaxoSmithKline's financials for the first quarter have been overshadowed by the news that it is selling Lucozade and Ribena in a move that could net the UK drugs giant in excess of £1 billion
Full story
-
April 17, 2013
Advisors to the FDABreo Ellip have given the thumbs up to GSK/Theravance's COPD inhaler Breo Ellipta, leaving the product just a hair's breadth away from approval for the all-important US market.
Full story
-
February 07, 2013
GlaxoSmithKline has posted a solid set of financials, unveiled plans to restructure its European operations and said it is considering the sale of its Ribena and Lucozade drinks
Full story
-
July 25, 2012
GlaxoSmithKline has posted second-quarter results which show that core operating profit was down 7% to just over £2.00 billion at constant exchange rates, while group turnover fell 2% to £6.46 billion
Full story
-
July 16, 2012
GlaxoSmithKline and partner Theravance have filed regulatory applications in the USA and European Union for their combination respiratory treatment which is seen as a successor to the blockbuster Advair/Seretide
Full story
-
April 26, 2012
GlaxoSmithKline has posted first-quarter results which have disappointed analysts and led to a near 3% fall in the UK major's share price
Full story
-
February 07, 2012
GlaxoSmithKline has posted a decent set of fourth-quarter results, though the main story was the increasing returns the UK drugs giant says it is getting from its R&D spend
Full story
-
January 10, 2012
Shares in GSK have taken a battering after the UK drugs major said it will push ahead with filings this year for its new COPD and asthma drug Relovair on the back of what some observers believe is unimpressive data
Full story
-
November 10, 2011
Mylan has bought rights to develop Pfizer's generic versions of GlaxoSmithKline's asthma and chronic obstructive pulmonary disorder blockbuster Advair
Full story
-
October 26, 2011
GlaxoSmithKline has just posted its third-quarter results which reveal a 3% increase in operating profit, before major restructuring, to £2.18 billion, while group turnover was up 3% at constant exchange rates, to £7.10 billion
Full story